Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BUPROPION HCL

All products: Limited Use (codes 315)

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Duloxetine (Cymbalta): general benefit, Not a benefit
  • Mirtazapine (Remeron RD): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Venlafaxine (Effexor XR): general benefit
  • Vortioxetine (Trintellix): general benefit
  • Desvenlafaxine (Pristiq): not a benefit

17 more in the class list below

Wellbutrin XL · DIN 02275090 · 150mg · extended release tablet

Limited Use — Reason for Use code 315 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 315 required
Write on scriptLU code 315 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315 For the treatment of depression. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Wellbutrin XL · DIN 02275090 Manufacturer: Valeant Canada Ltd.; listing date 2007-11-10 Health Canada: Marketed since 2021-06-11 · brand WELLBUTRIN XL · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 150 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1463 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76060 · Verify on the e-Formulary ↗ (DIN 02275090)

Source record
DIN 02275090: Wellbutrin XL Raw flags: sec12=Y, sec3=Y Item: 281604120; group id 453; item number 1128; lccId 00077; manufacturer id VAL Source form: ER Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6335; ministry $0.1463 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02275090 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76060
Interchangeable products
Act Bupropion XL · DIN 02439654 · $0.1463 Odan-Bupropion XL · DIN 02565838 · $0.1463 Taro-Bupropion XL · DIN 02475804 · $0.1463
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275090
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VENLAFAXINE HCL

· 45 products · General benefit · strengths: 37.5mg, 75mg, 150mg · ER Cap

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

DESVENLAFAXINE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications ZYBAN (bupropion hydrochloride) is indicated as smoking cessation treatment in conjunction with behavioural modification; nicotine replacement therapy may be used together with ZYBAN. Prior to a decision to prescribe a non-nicotine treatment including ZYBAN, thorough consideration should be given to the treatment option of nicotine replacement therapy alone. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see Potential association with behavioural and emotional changes, including self-harm). 1.2 Geriatrics Geriatrics (≥65 years of age): No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but because geriatric patients are more likely to have decreased renal function, greater sensitivity of some older individuals to bupropion cannot be ruled out (see Renal Impairment and 4 Dosage and Administration). https://pdf.hres.ca/dpd_pm/00080547.PDF PM date: 2025-05-16 Source product: ZYBAN; DIN 02238441; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Free programs for Smoking cessation (Ontario): Ontario Drug Benefit (ODB) Plan coverage of Champix® and Zyban® — coverage of varenicline (Champix®) and bupropion (Zyban®); generic varenicline and bupropion are Limited Use (Reason for Use code 423 for varenicline: 'For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling', limited to 12 weeks, 168 tablets, per 365 days; code 315 for bupropion) — patients who are seniors (age 65+), in long term-care homes, or those on social assistance (welfare or because of disability) — not stated (toronto.ca, Sep 9, 2026 ↗) Implementing STOP (Smoking Treatment for Ontario Patients) — publicly funded Nicotine Replacement Therapy (NRT) for your patients — residents of Ontario — free (intrepidlab.ca, Sep 9, 2026 ↗) STOP on the Net — free nicotine replacement therapy (NRT) patches and gum/lozenges for 6 weeks of treatment mailed to you within 2 weeks of enrollment — 18 years of age or older and lives within Ontario — free (intrepidlab.ca, Sep 9, 2026 ↗) Smokers' Helpline — quit coach for free, confidential, one-to-one support — patients who want tobacco use cessation counseling/support — free (toronto.ca, Sep 9, 2026 ↗) Pharmacy Smoking Cessation Program — smoking cessation counseling from a pharmacist — eligible ODB recipients — not stated (toronto.ca, Sep 9, 2026 ↗) The Guidebook also includes information on the Pharmacy Smoking Cessation Program for Ontario Drug Benefit recipients who want to quit smoking as part of the Ontario Government’s support to quit smoking. (ontario.ca, Updated August 24, 2023 ↗)